Skip to main content
OpenTrials
Completed

NCT Number: NCT03085576

NATional TUnisian REgistry of Atrial Fibrillation

A non-interventional, national longitudinal study of atrial fibrillation performed with 91 cardiologists.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

STCCCV - Société Tunisienne de Cardiologie et de Chirurgie Cardio-Vasculaire

Tunis, 1053, Tunisia

About this study

The NATURE-AF study is carried out in Tunisia at cardiology consultations in hospitals and in the liberal sector. A total of 91 cardiologists participate in the selection of patients as investigators. The study is a longitudinal non-interventional registry of atrial fibrillation. The data collected are managed by the DACIMA Clinical Suite® platform, which complies with international standards: FDA 21 CFR part 11 (Food and Drug Administration 21 Code of Federal Regulations part 11), HIPPA (Health Insurance Portability and Accountability Act), ICH (International Conference on Harmonisation), MedDRA (Medical Dictionary for Regulatory Activities). The DACIMA Clinical Suite® platform allows to track the data entered, check for inconsistencies and missing data, and schedule monitoring visits. A Steering Committee is set up to monitor patient inclusions, verify data sources, perform audit trails and prepare the statistical analysis plan for the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least one episode of atrial fibrillation, documented on a 12-lead ECG and / or a rhythmic holter (duration of the episode: 30 seconds or more)
  • Recent atrial fibrillation diagnosed for less than a year
  • Regular monitoring every 3 months is ensured
  • Informed, read and signed consent

Exclusion criteria

  • Estimated life expectancy at less than 12 months
  • Transient atrial fibrillation due to reversible cause (eg acute myocardial infarction, following cardiac surgery, acute alcohol intoxication, hyperthyroidism, pulmonary embolism or other acute pulmonary disease, pericarditis, myocarditis, hydro-electrolyte disorder, metabolic disorder)
  • Cardiac surgery ≤ 3 months
  • Atrial flutter isolated without atrial fibrillation
  • Mental disorders
  • Ongoing anticoagulation for reasons other than atrial fibrillation

Treatment and study plan

Primary outcomes

  1. Incidence of stroke or transient ischemic attack, thromboembolic events and cardiovascular death

    Time frame: Every 3 months up to 1 year

    Number of patients with ischemic stroke and/or transient ischemic attack, and/or arterial embolization during the follow-up period

Secondary outcomes

  1. Haemorrhagic accidents

    Time frame: Every 3 months up to 1 year

    All bleeding events (digestive, cerebral, other locations)

  2. Measurement of INR (International Normalized Ratio)

    Time frame: Every month for 1 year

    INR measurement of venous blood sampling

  3. TTR (percent Time in Therapeutic INR Range)

    Time frame: 1 year

    The mean TTR obtained in patients who received anticoagulant therapy

Sponsors and collaborators

Lead sponsor

Dacima Consulting

Other

Collaborators

  • Société Tunisienne de Cardiologie & de Chirurgie Cardio-Vasculaire

Registry information

Acronym: NATURE-AF

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Mar 21, 2017
Registry last updated
Apr 29, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.